Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results